Literature DB >> 10540370

Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system.

B G Weinshenker1.   

Abstract

Idiopathic inflammatory demyelinating diseases (IIDDs) of the central nervous system, of which multiple sclerosis is the prototype, represent a family of monophasic, recurrent or progressive diseases with overlapping clinical and pathological manifestations. While most patients recover spontaneously or following a brief course of high-dose corticosteroids, occasional patients, particularly those with fulminant severe IIDDs, such as the Marburg variant, do not respond to corticosteroids and have severe, residual neurological deficits. While it is widely believed that IIDDs are mediated by T lymphocytes, as is experimental allergic encephelomyelitis, additional, possibly humoral, factors may be essential to generate the extensive demyelination seen in these conditions. Anecdotal reports over the past two decades have suggested that patients with acute, severe neurological deficits resulting from IIDDs, who fail to improve after high-dose intravenous corticosteroids, may benefit from plasma exchange. A randomized, sham-controlled, crossover study has recently been completed at the Mayo Clinic, which addresses these observations. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10540370     DOI: 10.1002/(sici)1098-1101(1999)14:3<144::aid-jca7>3.0.co;2-r

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  8 in total

Review 1.  Corticosteroids and plasma exchange in multiple sclerosis.

Authors:  Hayretin Tumani
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

2.  Cerebral tumefactive demyelinating lesions.

Authors:  Wei Qi; G E Jia; Xinsheng Wang; Maozhi Zhang; Zhenyu Ma
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

Review 3.  Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist.

Authors:  Roberto A Cruz; Sana Chaudhary; Myriam Guevara; Ethan Meltzer
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

4.  Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study.

Authors:  Shaoying Tan; Tsz Kin Ng; Quangang Xu; Mo Yang; Yuan Zhuang; Jie Zhao; Huanfen Zhou; Da Teng; Shihui Wei
Journal:  Ther Adv Neurol Disord       Date:  2020-08-21       Impact factor: 6.570

Review 5.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

6.  Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.

Authors:  Nasim Tabrizi; Masoud Etemadifar; Fereshteh Ashtari; Arash Zahed; Fatemeh Etemadifar
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

Review 7.  Demyelinating disorders: update on transverse myelitis.

Authors:  Chitra Krishnan; Adam I Kaplin; Carlos A Pardo; Douglas A Kerr; Sanjay C Keswani
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 6.030

8.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.